SCHEMBL2398837

SCHEMBL2398837

CC(C)(Sc1nc(CCOc2ccc(-c3ccc(F)cc3)cc2)cs1)C(=O)O

nearest known ligand 0.49

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 2/20 0.49
POLB P06746 1/20 0.41
PPARA Q07869 5/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
NPC1 O15118 1/20 0.41
ALDH1A1 P00352 1/20 0.41
LMNA P02545 3/20 0.41
TP53 P04637 2/20 0.41
SLC22A12 Q96S37 1/20 0.40
CXCR2 P25025 1/20 0.39
PPARG P37231 2/20 0.38
PPARD Q03181 2/20 0.38
FFAR1 O14842 1/20 0.38
MEN1 O00255 1/20 0.37
MAPT P10636 1/20 0.37
KMT2A Q03164 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2413830 0.95 RAB9A (0.53) RAB9APOLBPPARASMN1; SMN2CXCR2
SCHEMBL2415153 0.93 PPARA (0.45) RAB9APPARASMN1; SMN2NPC1LMNA
SCHEMBL2408505 0.92 TP53 (0.45) RAB9APPARASMN1; SMN2LMNATP53
SCHEMBL2412515 0.92 RAB9A (0.47) RAB9APOLBPPARASMN1; SMN2NPC1
SCHEMBL2419262 0.92 PPARA (0.46) RAB9APPARASMN1; SMN2ALDH1A1LMNA
SCHEMBL2413735 0.91 RAB9A (0.43) RAB9APOLBPPARASMN1; SMN2NPC1
SCHEMBL2413963 0.91 PPARA (0.45) PPARALMNATP53SLC22A12PPARG
SCHEMBL2413710 0.91 RAB9A (0.46) RAB9APOLBPPARASMN1; SMN2TP53
SCHEMBL2410233 0.91 SHMT2 (0.42) RAB9APPARASMN1; SMN2PPARGPPARD
SCHEMBL2410536 0.91 PPARA (0.43) PPARASMN1; SMN2LMNATP53SLC22A12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8026370-B2 Peroxisome proliferator antagonist; hyperlipemia agents; arteriosclerosis; antiischemic agents MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-09-27 US claimed
US-20080167307-A1 Carboxylic Acid Derivative Containing Thiazole Ring and Pharmaceutical Use Thereof MITSUBISHI PHAMA CORPORATION (JP) 2008-07-10 US claimed
EP-1816128-A1 CARBOXYLIC ACID DERIVATIVE CONTAINING THIAZOLE RING AND PHARMACEUTICAL USE THEREOF Mitsubishi Pharma Corporation (JP) 2007-08-08 EP claimed
EP-2380884-B1 CARBOXYLIC ACID DERIVATIVE CONTAINING THIAZOLE RING AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORP (JP) 2014-02-12 EP disclosed
US-8497382-B2 Carboxylic acid derivative containing thiazole ring and pharmaceutical use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2013-07-30 US disclosed
EP-2380884-A1 CARBOXYLIC ACID DERIVATIVE CONTAINING THIAZOLE RING AND PHARMACEUTICAL USE THEREOF Mitsubishi Tanabe Pharma Corporation (JP) 2011-10-26 EP disclosed
US-20110237630-A1 CARBOXYLIC ACID DERIVATIVE CONTAINING THIAZOLE RING AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-09-29 US disclosed
US-8026370-B2 Peroxisome proliferator antagonist; hyperlipemia agents; arteriosclerosis; antiischemic agents MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-09-27 US disclosed
US-8026370-B2 Peroxisome proliferator antagonist; hyperlipemia agents; arteriosclerosis; antiischemic agents MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-09-27 US disclosed
US-8026370-B2 Peroxisome proliferator antagonist; hyperlipemia agents; arteriosclerosis; antiischemic agents MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-09-27 US disclosed
US-20080167307-A1 Carboxylic Acid Derivative Containing Thiazole Ring and Pharmaceutical Use Thereof MITSUBISHI PHAMA CORPORATION (JP) 2008-07-10 US disclosed
US-20080167307-A1 Carboxylic Acid Derivative Containing Thiazole Ring and Pharmaceutical Use Thereof MITSUBISHI PHAMA CORPORATION (JP) 2008-07-10 US disclosed
EP-1816128-A1 CARBOXYLIC ACID DERIVATIVE CONTAINING THIAZOLE RING AND PHARMACEUTICAL USE THEREOF Mitsubishi Pharma Corporation (JP) 2007-08-08 EP disclosed
EP-1816128-A1 CARBOXYLIC ACID DERIVATIVE CONTAINING THIAZOLE RING AND PHARMACEUTICAL USE THEREOF Mitsubishi Pharma Corporation (JP) 2007-08-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080167307-A1 Carboxylic Acid Derivative Containing Thiazole Ring and Pharmaceutical Use Thereof PPARA, PPARD, PPARG RAB9A 2891/4885POLB 3392/4885PPARA 1/4885
US-20110237630-A1 CARBOXYLIC ACID DERIVATIVE CONTAINING THIAZOLE RING AND PHARMACEUTICAL USE THEREOF PPARA, PPARD, PPARG RAB9A 3488/4885POLB 2897/4885PPARA 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.